As better appetite control builds, increasing doses help manage both cravings and eating patterns
Its defining pharmacological feature is negligible cortisol and prolactin co-stimulation at GH-stimulating doses, making it the preferred compound in research protocols where isolated GH-axis stimulation is required
Brett, MD Medical Reviewer Marie Suszynski Author Marie Suszynski is a Pennsylvania-based freelance health journalist who writes authoritative stories on a wide range of topics, including diabetes, arthritis, and more with a focus
Beyond the GLP-1 system, several other feeding/metabolic endocrine pathways have also shown promise as potential pharmacotherapeutic targets for AUD and/or obesity, including (but not limited to) ghrelin [238,239,240,241,242,243], orexins [244,245,246,247,248], amylin [249,250,251,252], and fibroblast growth factor 21 [253,254,255,256]
Sig Transduct Target Ther 9 , 234 (2024)